NCT03888014 is a clinical trial of GLOW800 in Vascular; Lesion, Central Nervous System, sponsored by Cedars-Sinai Medical Center.

Who is sponsoring NCT03888014?

NCT03888014 is sponsored by Cedars-Sinai Medical Center.

What drugs are being tested in NCT03888014?

Interventions in NCT03888014: GLOW800, indocyanine green (ICG).

What condition does NCT03888014 study?

NCT03888014 studies Vascular; Lesion, Central Nervous System, Brain Tumor, Cerebral Aneurysm, Cerebral AVM.

Is NCT03888014 still recruiting?

NCT03888014 is currently completed. Last updated 18 January 2023.

Last reviewed 2023-01-18 · How we verify

NCT03888014

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraoperative Fluorescence With Augmented Reality

Completed Last updated 18 January 2023

What this trial tests

trial testing GLOW800 in Vascular; Lesion, Central Nervous System in 7 participants. Completed in 1 June 2021.

Timeline

1 July 2019

Primary endpoint
1 June 2021

1 June 2021

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	7
Start date	1 July 2019
Primary completion	1 June 2021
Estimated completion	1 June 2021
Sites	1 location across United States

Drugs / interventions tested

GLOW800
indocyanine green (ICG) — full drug profile →

Conditions studied

Vascular; Lesion, Central Nervous System — all drugs for Vascular; Lesion, Central Nervous System →
Brain Tumor — all drugs for Brain Tumor →
Cerebral Aneurysm — all drugs for Cerebral Aneurysm →
Cerebral AVM — all drugs for Cerebral AVM →

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Vascular; Lesion, Central Nervous System or Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study looking at a new way to evaluate vascular problems or tumors in brain surgery patients using a standard \& approved intravenous dye and augmented reality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03888014 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
Last refreshed: 18 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03888014.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing